Cargando…

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

The FDA-approved starting dosage of capecitabine is 1,250 mg/m(2), and market research indicates that U.S. physicians routinely prescribe 1,000 mg/m(2). Retrospective analyses however report reduced toxicity and efficacy in a subset of patients with the 3R/3R genotype of the thymidylate synthase gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soo, Ross Andrew, Syn, Nicholas, Lee, Soo-Chin, Wang, Lingzhi, Lim, Xn-Yii, Loh, Marie, Tan, Sing-Huang, Zee, Ying-Kiat, Wong, Andrea Li-Ann, Chuah, Benjamin, Chan, Daniel, Lim, Siew-Eng, Goh, Boon-Cher, Soong, Richie, Yong, Wei-Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906519/ https://www.ncbi.nlm.nih.gov/pubmed/27296624 http://dx.doi.org/10.1038/srep27826

Ejemplares similares

Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study
por: Syn, Nicholas Li‐Xun, et al.
Publicado: (2016)

Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis
por: Sim, Wilson, et al.
Publicado: (2021)

Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models
por: Syn, Nicholas L., et al.
Publicado: (2018)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

Capecitabine for primary breast cancer
por: Toi, Masakazu, et al.
Publicado: (2017)

Different treatment efficacies and side effects of cytotoxic chemotherapy
por: Li, Low-Jia, et al.
Publicado: (2020)

Characterization and Establishment of a Novel EBV Strain Simultaneously Associated With Nasopharyngeal Carcinoma and B-Cell Lymphoma
por: Yu, Fenggang, et al.
Publicado: (2021)

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
por: Wong, Andrea Li Ann, et al.
Publicado: (2015)

Pharmacogenetics and pharmacogenomics: practical applications in routine medical practice
por: Maitland-van der Zee, Anke-Hilse, et al.
Publicado: (2010)

Systematic Review of Pharmacogenetic Warfarin Dosing
por: van Schie, Rianne M. F., et al.
Publicado: (2009)

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Intermittent Feeding Schedules—Behavioural Consequences and Potential Clinical Significance
por: Murphy, Michelle, et al.
Publicado: (2014)

High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients
por: Tan, Sing-Huang, et al.
Publicado: (2015)

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics
por: Lennard, Lynne, et al.
Publicado: (2014)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

High-risk HPV genotypes and P16INK4a expression in a cohort of head and neck squamous cell carcinoma patients in Singapore
por: Tan, Louise Soo Yee, et al.
Publicado: (2016)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

Finite-size effects in transcript sequencing count distribution: its power-law correction necessarily precedes downstream normalization and comparative analysis
por: Wong, Wing-Cheong, et al.
Publicado: (2018)

Clinical Potential of DNA Methylation in Gastric Cancer: A Meta-Analysis
por: Sapari, Nur Sabrina, et al.
Publicado: (2012)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique
por: Heong, Valerie, et al.
Publicado: (2020)

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
por: Wang, Lingzhi, et al.
Publicado: (2017)

Clinical Outcome among Nasopharyngeal Cancer Patients in a Multi-Ethnic Society in Singapore
por: Mak, Han Wen, et al.
Publicado: (2015)

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
por: Soo, Ross A., et al.
Publicado: (2018)

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
por: Syn, Nicholas L., et al.
Publicado: (2018)

miREM: an expectation-maximization approach for prioritizing miRNAs associated with gene-set
por: Abdul Hadi, Luqman Hakim, et al.
Publicado: (2018)

Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review
por: Cadoo, Karen A, et al.
Publicado: (2016)

Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
por: Li, Jiaqi, et al.
Publicado: (2020)

Re-thinking the possible interaction between proton pump inhibitors and capecitabine
por: Jeong, Soo Hee, et al.
Publicado: (2022)

Resilience in the Surgical Scheduling to Support Adaptive Scheduling System
por: Wiyartanti, Lisa, et al.
Publicado: (2020)

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
por: Wang, Tingting, et al.
Publicado: (2015)

Cancer pharmacogenetics
por: Marsh, S, et al.
Publicado: (2004)

Experimental Pharmacogenetics
por: Lubs, Herbert A.
Publicado: (1964)

Pharmacogenetics of Anticoagulants
por: Rane, Anders, et al.
Publicado: (2010)

Pharmacogenetics of osteoporosis
por: Marini, Francesca, et al.
Publicado: (2010)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j4gdtg1at94mi2ifverlajv29p